secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001651308-24-000164
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene enters $400M unsecured credit facility with China Merchants Bank
------------------------------------------------------------------------

- Facility dated Dec 9, 2024; $400M uncommitted, unsecured, revolving; SOFR-based floating rate.
- Proceeds for daily operations and refinancing existing working capital loans.
- Company plans to repay $300M of existing $380M drawn facility in Dec 2024; remaining $80M in Jan 2025.
- Covenants include liabilities-to-equity ratio, minimum consolidated net assets and cash balance tested quarterly.
- No borrowings outstanding under new facility as of filing date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000164/0001651308-24-000164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000164/bgne-20241209.htm
  HTML page:      https://secwatch.observer/filing/0001651308-24-000164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer